Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Doumerc

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
European Urology Oncology|June 27, 2024
Robot-assisted Partial Nephrectomy for Hilar and Nonhilar Renal Masses: Comparison of Perioperative, Oncological, and Functional Results in a Multicentre Prospective Cohort (NEPRAH Study, UroCCR 175)Julien Sarkis, Cecile M Champy, Nicolas Doumerc, et al.
Cancer|October 8, 2025
Racial differences in kidney cancer histology and outcome: A nationwide study from the UroCCR CohortXiaofan Lu, Jean-Christophe Bernhard, Gaëlle Margue, et al.
BJU International|January 17, 2023
Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15)Astrid Boulenger de Hauteclocque, Loïc Ferrer, Damien Ambrosetti, et al.
European Urology Open Science|March 4, 2025
Renal Mass Biopsy Prior to Surgical Excision: Practice, Diagnostic Performance, and Impact on Management in the UroCCR Registry (Ancillary Study No. 118)Pauline Proye, Bastien Gondran-Tellier, Floriane Michel, et al.
Minerva Urology and Nephrology|September 25, 2024
Oncologic surveillance after surgical treatment for clinically localized kidney cancer: UroCCR study n. 129Alberto Martini, Jean-Christophe Bernhard, Ugo G Falagario, et al.
The Lancet. Oncology|April 7, 2022
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trialYann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
European Urology Oncology|June 27, 2024
Robot-assisted Partial Nephrectomy for Hilar and Nonhilar Renal Masses: Comparison of Perioperative, Oncological, and Functional Results in a Multicentre Prospective Cohort (NEPRAH Study, UroCCR 175)Julien Sarkis, Cecile M Champy, Nicolas Doumerc, et al.
Cancer|October 8, 2025
Racial differences in kidney cancer histology and outcome: A nationwide study from the UroCCR CohortXiaofan Lu, Jean-Christophe Bernhard, Gaëlle Margue, et al.
BJU International|January 17, 2023
Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15)Astrid Boulenger de Hauteclocque, Loïc Ferrer, Damien Ambrosetti, et al.
European Urology Open Science|March 4, 2025
Renal Mass Biopsy Prior to Surgical Excision: Practice, Diagnostic Performance, and Impact on Management in the UroCCR Registry (Ancillary Study No. 118)Pauline Proye, Bastien Gondran-Tellier, Floriane Michel, et al.
Minerva Urology and Nephrology|September 25, 2024
Oncologic surveillance after surgical treatment for clinically localized kidney cancer: UroCCR study n. 129Alberto Martini, Jean-Christophe Bernhard, Ugo G Falagario, et al.
The Lancet. Oncology|April 7, 2022
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trialYann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, et al.
Pageof 10